ZIOPHARM ONCOLOGY INC's ticker is ZIOP and the CUSIP is 98973P101. A total of 170 filers reported holding ZIOPHARM ONCOLOGY INC in Q4 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $83,156 | -73.3% | 630,945 | +3.3% | 0.00% | -100.0% |
Q2 2023 | $311,376 | -19.3% | 610,545 | -0.3% | 0.00% | 0.0% |
Q1 2023 | $385,777 | +7.6% | 612,345 | +10.9% | 0.00% | 0.0% |
Q4 2022 | $358,363 | -64.2% | 552,229 | -5.2% | 0.00% | -50.0% |
Q3 2022 | $1,002,000 | +39.9% | 582,740 | +0.9% | 0.00% | 0.0% |
Q2 2022 | $716,000 | +58.4% | 577,368 | +1.7% | 0.00% | +100.0% |
Q1 2022 | $452,000 | -0.2% | 567,777 | +36.4% | 0.00% | 0.0% |
Q4 2021 | $453,000 | -44.6% | 416,410 | -7.3% | 0.00% | -50.0% |
Q3 2021 | $817,000 | -9.8% | 448,984 | +30.7% | 0.00% | 0.0% |
Q2 2021 | $906,000 | -27.2% | 343,455 | -0.7% | 0.00% | -33.3% |
Q1 2021 | $1,245,000 | +79.4% | 345,920 | +25.6% | 0.00% | +50.0% |
Q4 2020 | $694,000 | +48.0% | 275,474 | +48.2% | 0.00% | +100.0% |
Q3 2020 | $469,000 | -25.9% | 185,851 | -3.7% | 0.00% | -50.0% |
Q2 2020 | $633,000 | +72.5% | 192,993 | +32.3% | 0.00% | 0.0% |
Q1 2020 | $367,000 | – | 145,861 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 9,709,607 | $60,394,000 | 3.07% |
MSD Partners, L.P. | 3,410,500 | $21,213,000 | 1.32% |
MILLER VALUE PARTNERS, LLC | 4,926,456 | $30,643,000 | 1.24% |
Michael & Susan Dell Foundation | 66,749 | $415,000 | 0.33% |
ACUTA CAPITAL PARTNERS, LLC | 150,000 | $933,000 | 0.26% |
Piermont Capital Management Inc. | 85,500 | $532,000 | 0.15% |
A.R.T. Advisors, LLC | 411,547 | $2,559,000 | 0.14% |
EQUITEC PROPRIETARY MARKETS, LLC | 96,100 | $598,000 | 0.14% |
Vident Investment Advisory, LLC | 204,744 | $1,274,000 | 0.10% |
EQUITEC PROPRIETARY MARKETS, LLC | 68,800 | $428,000 | 0.10% |